Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

Inclusion Criteria: * NSCLC confirmed by histopathology or cytology; * Stage IIA or IIIB NSCLC according to Tumor Node Metastasis (TMN) staging of Lung Staging Standard version 7 2009, and be unresectable; * Has active mutation of EGFR in exon 19 or 21; * Has measurable lesion \[according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, must have at least one evaluable lesion with the longest dimension \>= 10mm; if the evaluable lesion is lymph node, the shortest dimension should be measured and \>=15mm\]; * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; * expectancy life \>= 12 weeks; Exclusion Criteria: * Had be treated by HER-targeting agents; * Had systemic anit-NSCLC treatments; * Had local radiotherapy for NSCLC; * Has upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer; * Diagnosed other malignant tumor besides NSCLC within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival, cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor); * Any evidence to indicate moderate or severe chronic obstructive pulmonary disease (COPD); * Known hypersensitivity to platinum, etoposide, EGFR-Tyrosine Kinase Inhibitor (TKI) agents or relevant components in the formulation; * Uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection;